The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.
Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.
FDA developing guidelines for oncology endpoints.
Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.
Michelle Le Beau named director of University of Chicago Cancer Research Center.
Funding opportunities listed.
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
